StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.02−0.08 (-1.13%)

Close on Nov 17, 2026Market cap $254.77MP/E –Yield –

Evommune operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Evommune's operating cash flow for the twelve months ending Sep 30, 2026 was -$90.40M. For fiscal 2025 it was -$76.44M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$76.44M–
FY2024Dec 31, 2024-$58.20M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$25.88M–
Q2 FY2026Jun 30, 2026-$20.32M–
Q1 FY2026Mar 31, 2026-$27.50M–
Q4 FY2025Dec 31, 2025-$16.70M–
Q3 FY2025Sep 30, 2025-$9.64M–
Q2 FY2025Jun 30, 2025-$26.21M–
Q1 FY2025Mar 31, 2025-$23.90M–
Q4 FY2024Dec 31, 2024-$18.51M–

More Evommune figures

See a number that looks wrong?